Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients—a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN)
Pediatric Nephrology · 2025-02 · 40 (2) · 491-503
DOI: 10.1007/s00467-024-06487-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Nephrology, online erschienen am 16.09.2024. Verfasst von Alexander Fichtner und 28 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg University, Medical Faculty Heidelberg, Department of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidel…. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council, Medizinische Fakultät Heidelberg der Universität Heidelberg.
Abstract (Originalsprache)
Background
This study by the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) was designed to determine the incidence, risk factors, current management strategies, and outcomes of antibody-mediated rejection (ABMR) in pediatric kidney transplant recipients (pKTR).
Methods
We performed an international, multicenter, longitudinal cohort study of data reported to the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry. Three hundred thirty-seven pKTR from 21 European centers were analyzed. Clinical outcomes, including kidney dysfunction, rejection, HLA donor-specific antibodies, BK polyomavirus-associated (BKPyV) nephropathy, and allograft loss, were assessed through 5 years post-transplant.
Results
The cumulative incidence of de novo donor-specific class I HLA antibodies (HLA-DSA) post-transplant was 4.5% in year 1, 8.3% in year 3, and 13% in year 5; the corresponding data for de novo class II HLA-DSA were 10%, 22.5%, and 30.6%, respectively. For 5 years post-transplant, the cumulative incidence of acute ABMR was 10% and that of chronic active ABMR was 5.9%. HLA-DR mismatch and de novo HLA-DSA, especially double positivity for class I and class II HLA-DSA, were significant risk factors for ABMR, whereas cytomegalovirus (CMV) IgG negative recipient and CMV IgG negative donor were associated with a lower risk. BKPyV nephropathy was associated with the highest risk of graft dysfunction, followed by ABMR, T-cell mediated rejection, and older donor age.
Conclusions
This study provides an estimate of the incidence of de novo HLA-DSA and ABMR in pKTR and highlights the importance of BKPyV nephropathy as a strong risk factor for allograft dysfunction. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heidelberg University, Medical Faculty Heidelberg, Department of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany. alexander.fichtner@med.uni-heidelberg.de.
- Heidelberg University, Medical Faculty Heidelberg, Department of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
- Heidelberg University, Medical Faculty Heidelberg, Institute of Immunology, Transplantation Immunology, Heidelberg, Germany.
- Transplant Immunology Research Center of Excellence, Koç University, Istanbul, Turkey.
- Heidelberg University, Medical Faculty Heidelberg, Department of Pathology, Heidelberg, Germany.
- Pediatric Nephrology and Renal Transplant Unit, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Förderung
- H2020 European Research Council
- Medizinische Fakultät Heidelberg der Universität Heidelberg
Zitieren
APA
Fichtner, A., Gauché, L., Süsal, C., Tran, T. H., Waldherr, R., Krupka, K., Guzzo, I., Carraro, A., Oh, J., Zirngibl, M., Weitz, M., König, J., Büscher, A., Berta, L., Simon, T., Awan, A., Rusai, K., Topaloglu, R., Peruzzi, L., …, & CERTAIN study group (2025). Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients—a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN). Pediatric Nephrology, 40(2), 491-503. https://doi.org/10.1007/s00467-024-06487-2
Vancouver
Fichtner A, Gauché L, Süsal C, Tran TH, Waldherr R, Krupka K, et al. Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients—a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN). Pediatric Nephrology. 2025;40(2):491-503. doi:10.1007/s00467-024-06487-2
BibTeX
@article{Fichtner2025,
author = {Fichtner, Alexander and Gauché, Laura and Süsal, Caner and Tran, Thuong Hien and Waldherr, Rüdiger and Krupka, Kai and Guzzo, Isabella and Carraro, Andrea and Oh, Jun and Zirngibl, Matthias and Weitz, Marcus and König, Jens and Büscher, Anja and Berta, Laszlo and Simon, Thomas and Awan, Atif and Rusai, Krisztina and Topaloglu, Rezan and Peruzzi, Licia and Printza, Nikoleta and Kim, Jon Jin and Weber, Lutz T and Melk, Anette and Pape, Lars and Rieger, Susanne and Patry, Christian and Höcker, Britta and Tönshoff, Burkhard and CERTAIN study group, CERTAIN study group},
title = {Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients—a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN)},
journal = {Pediatric Nephrology},
year = {2025},
volume = {40},
number = {2},
pages = {491--503},
doi = {10.1007/s00467-024-06487-2}
}
EUVIMED